Drug intelligence / Profile preview

SNP837

Development stage: Preclinical
Lead developer: SciNeuro Pharmaceuticals
Administration: Parenteral

Overview

SNP837 is a blood-brain barrier (BBB) shuttle platform developed by SciNeuro Pharmaceuticals. The technology is designed to facilitate the delivery of various therapeutic modalities, including monoclonal antibodies and other large molecules, into the central nervous system (CNS). By enabling these agents to cross the restrictive BBB, SNP837 aims to address a major challenge in CNS drug development, potentially enhancing the brain penetration and therapeutic efficacy of treatments for neurological and neurodegenerative diseases.

Beyond the preview

Go deeper on SNP837.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNP837.

Explore the full profile